A Program To Accelerate Sales

AbbVie seeks EMA marketing authorisation for preventive migraine therapy

The MAA is based on data from two Phase III trials of atogepant in adult patients with episodic and chronic migraine.


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.